BR112012016982A2 - "bactérias probióticas recombinantes para a prevenção e tratamento da doença inflamatória do intestino (ibd) e síndrome do intestino irritável (ibs)". - Google Patents
"bactérias probióticas recombinantes para a prevenção e tratamento da doença inflamatória do intestino (ibd) e síndrome do intestino irritável (ibs)".Info
- Publication number
- BR112012016982A2 BR112012016982A2 BR112012016982A BR112012016982A BR112012016982A2 BR 112012016982 A2 BR112012016982 A2 BR 112012016982A2 BR 112012016982 A BR112012016982 A BR 112012016982A BR 112012016982 A BR112012016982 A BR 112012016982A BR 112012016982 A2 BR112012016982 A2 BR 112012016982A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- ibs
- active fraction
- ibd
- treatment
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract 3
- 208000002551 irritable bowel syndrome Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000006041 probiotic Substances 0.000 title abstract 2
- 230000000529 probiotic effect Effects 0.000 title abstract 2
- 235000018291 probiotics Nutrition 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 12
- 102000004169 proteins and genes Human genes 0.000 abstract 8
- 102100023795 Elafin Human genes 0.000 abstract 4
- 101001048718 Homo sapiens Elafin Proteins 0.000 abstract 4
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 abstract 3
- 229960003147 reserpine Drugs 0.000 abstract 3
- 241000270295 Serpentes Species 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR10305045.6 | 2010-01-14 | ||
EP10305045 | 2010-01-14 | ||
PCT/EP2011/050489 WO2011086172A1 (en) | 2010-01-14 | 2011-01-14 | Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (ibd) and irritable bowel syndrome (ibs) |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112012016982A2 true BR112012016982A2 (pt) | 2016-12-13 |
BR112012016982B1 BR112012016982B1 (pt) | 2021-02-09 |
BR112012016982B8 BR112012016982B8 (pt) | 2022-12-20 |
Family
ID=42224980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012016982A BR112012016982B8 (pt) | 2010-01-14 | 2011-01-14 | bactéria de ácido lático recombinante de grau alimentício e composição terapêutica |
Country Status (10)
Country | Link |
---|---|
US (3) | US20120195859A1 (pt) |
EP (1) | EP2451467B1 (pt) |
JP (1) | JP6007106B2 (pt) |
KR (1) | KR101667982B1 (pt) |
CN (1) | CN102740867A (pt) |
AU (1) | AU2011206532B8 (pt) |
BR (1) | BR112012016982B8 (pt) |
CA (1) | CA2786847C (pt) |
ES (1) | ES2613755T3 (pt) |
WO (1) | WO2011086172A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
FR2990699B1 (fr) | 2012-05-21 | 2016-02-05 | Agronomique Inst Nat Rech | Cassettes d'expression procaryotes regulees par le stress |
WO2013188529A1 (en) * | 2012-06-15 | 2013-12-19 | Temple University Of The Commonwealth System Of Higher Education | Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium |
EP2706067A1 (en) * | 2012-09-06 | 2014-03-12 | Humboldt-Universität zu Berlin | Probiotic bacteria as carrier for a helminth-derived immunomodulator for the treatment of inflammatory disorders |
US20150283144A1 (en) | 2012-11-01 | 2015-10-08 | Rijksuniversiteit Groningen | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
EP2851086A1 (en) | 2013-09-20 | 2015-03-25 | Sanofi | Serpins: methods of therapeutic ß-cell regeneration and function |
US20160002316A1 (en) | 2013-02-22 | 2016-01-07 | Joslin Diabetes Center | Serpins: methods of therapeutic beta-cell regeneration and function |
EP2769732A1 (en) | 2013-02-22 | 2014-08-27 | Sanofi | Serpins: methods of therapeutic beta-cell regeneration and function |
EP2988761A1 (en) | 2013-03-05 | 2016-03-02 | Rijksuniversiteit Groningen | Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation. |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
WO2015168534A1 (en) * | 2014-05-02 | 2015-11-05 | Novogy, Inc. | Therapeutic treatment of gastrointestinal microbial imbalances through competitive microbe displacement |
KR101787543B1 (ko) | 2014-08-22 | 2017-10-19 | 샘표식품 주식회사 | 발효배양 산삼을 포함하는 항염증 조성물 |
WO2016124239A1 (en) | 2015-02-04 | 2016-08-11 | Aurealis Oy | Recombinant probiotic bacteria for use in the treatment of a skin dysfunction |
CN105106246A (zh) * | 2015-08-20 | 2015-12-02 | 江南大学 | 一种植物乳杆菌zs2058及其用途 |
US20180355023A1 (en) * | 2015-09-21 | 2018-12-13 | Vithera Pharmaceuticals, Inc. | Treatment of disease with lactic acid bacteria having stably integrated trappin-2 |
MA45288A (fr) * | 2016-06-08 | 2019-04-17 | Sofar Spa | Nouvelle utilisation médicale de probiotiques |
US10829563B2 (en) | 2016-06-16 | 2020-11-10 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Method of screening a candidate compound for activity as an elastase 2A (ELA2A) inhibitor |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
CN110331148B (zh) * | 2019-08-20 | 2021-05-04 | 华中农业大学 | 一种编码IFNα蛋白的基因、重组载体pELSH-IFNα、重组干酪乳杆菌及应用 |
EP4051379A4 (en) * | 2019-10-29 | 2023-12-13 | The Regents of the University of California | THERAPEUTIC APPROACH FOR THE TREATMENT OF AN INFLAMMATORY ABDOMINAL CONDITION |
CN111617099B (zh) * | 2020-06-16 | 2022-12-20 | 青岛农业大学 | 一种无抗高细胞亲和性结肠炎修复剂与应用方法 |
EP4210722A1 (en) * | 2020-09-07 | 2023-07-19 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods of treatment of inflammatory bowel diseases |
CN113684162B (zh) * | 2021-06-03 | 2024-02-27 | 江南大学 | 一种表达小鼠防御素mBD14基因的重组植物乳杆菌及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5734014A (en) * | 1992-08-11 | 1998-03-31 | Tsumura & Co. | Elafin derivative |
IT1270123B (it) * | 1994-10-05 | 1997-04-28 | Dompe Spa | Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia |
JPH10127292A (ja) * | 1996-10-31 | 1998-05-19 | Tsumura & Co | エラフィン類発現ベクターおよびこれを利用したエラフィン類の製造法 |
FR2787810B1 (fr) | 1998-12-24 | 2002-10-31 | Inst Nat De La Rech Agronomique Inra | Bacteries a gram positif depourvues d'activite proteasique htra, et leurs utilisations |
DE10101793A1 (de) * | 2001-01-17 | 2002-08-01 | Manfred Nilius | Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen |
EP1227152A1 (en) * | 2001-01-30 | 2002-07-31 | Société des Produits Nestlé S.A. | Bacterial strain and genome of bifidobacterium |
US7780961B2 (en) * | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
JP2005529622A (ja) * | 2002-06-19 | 2005-10-06 | ヴェーイーベー・ヴェーゼットウェー | 腸吸収を促進するための方法および手段 |
FR2843973B1 (fr) | 2002-08-30 | 2006-07-07 | Agronomique Inst Nat Rech | Cassettes d'expression procaryotes regulees par le zinc |
AU2003298291A1 (en) * | 2002-11-15 | 2004-06-15 | Universiteit Gent | Self-containing lactobacillus strain |
US7157233B2 (en) * | 2004-03-24 | 2007-01-02 | Tripath Imaging, Inc. | Methods and compositions for the detection of cervical disease |
KR20070026575A (ko) * | 2004-05-18 | 2007-03-08 | 브이아이비 브이지더블유 | 자족형 락토바실러스 균주 |
-
2011
- 2011-01-14 EP EP11700274.1A patent/EP2451467B1/en active Active
- 2011-01-14 ES ES11700274.1T patent/ES2613755T3/es active Active
- 2011-01-14 BR BR112012016982A patent/BR112012016982B8/pt active IP Right Grant
- 2011-01-14 JP JP2012548450A patent/JP6007106B2/ja active Active
- 2011-01-14 KR KR1020127018224A patent/KR101667982B1/ko active IP Right Grant
- 2011-01-14 WO PCT/EP2011/050489 patent/WO2011086172A1/en active Application Filing
- 2011-01-14 CN CN2011800053677A patent/CN102740867A/zh active Pending
- 2011-01-14 CA CA2786847A patent/CA2786847C/en active Active
- 2011-01-14 AU AU2011206532A patent/AU2011206532B8/en active Active
-
2012
- 2012-01-24 US US13/357,063 patent/US20120195859A1/en not_active Abandoned
-
2013
- 2013-05-21 US US13/899,179 patent/US20130344033A1/en not_active Abandoned
-
2014
- 2014-09-18 US US14/490,161 patent/US9688742B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2011206532B2 (en) | 2015-07-30 |
CA2786847A1 (en) | 2011-07-21 |
AU2011206532A8 (en) | 2015-08-06 |
BR112012016982B8 (pt) | 2022-12-20 |
BR112012016982B1 (pt) | 2021-02-09 |
US20150073125A1 (en) | 2015-03-12 |
ES2613755T3 (es) | 2017-05-25 |
WO2011086172A1 (en) | 2011-07-21 |
CA2786847C (en) | 2017-08-01 |
AU2011206532A1 (en) | 2012-07-19 |
EP2451467A1 (en) | 2012-05-16 |
KR20120116435A (ko) | 2012-10-22 |
KR101667982B1 (ko) | 2016-10-20 |
AU2011206532B8 (en) | 2015-08-06 |
US20130344033A1 (en) | 2013-12-26 |
JP2013517256A (ja) | 2013-05-16 |
JP6007106B2 (ja) | 2016-10-12 |
EP2451467B1 (en) | 2016-12-21 |
US20120195859A1 (en) | 2012-08-02 |
CN102740867A (zh) | 2012-10-17 |
US9688742B2 (en) | 2017-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012016982A2 (pt) | "bactérias probióticas recombinantes para a prevenção e tratamento da doença inflamatória do intestino (ibd) e síndrome do intestino irritável (ibs)". | |
Garcia-Gutierrez et al. | Gut microbiota as a source of novel antimicrobials | |
Hanchi et al. | Inhibition of MRSA and of Clostridium difficile by durancin 61A: synergy with bacteriocins and antibiotics | |
MX350325B (es) | Bacteria para usarse como un probiotico para aplicaciones nutricionales y medicas. | |
CY1119892T1 (el) | Φορεις και αλληλουχιες για την αγωγη ασθενειων | |
BR112012027055A2 (pt) | agente estabilizante para proteínas farmacêuticas. | |
EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
BR112013000097A2 (pt) | composições e métodos relacionados a variantes da proteína a (spa) | |
CY1117655T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
WO2011110655A3 (en) | Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease | |
CY1116728T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
BRPI1010830A2 (pt) | Sequências de aminoácidos melhoradas direcionadas contra o vírus respiratório sencicial humano (hrsv) e polipetídeos que compreende os mesmos para prevenção e/ou tratamento de infecções do trato respiratório. | |
BR112012010398A2 (pt) | metodo para reduzir a inflamação gastrointestinal usando a bactéria bifidobacterium animalis ou um produto laticínio fermentado compreendendo tal bactéria | |
BR112015023140A8 (pt) | proteínas de fusão, método para a fabricação da proteína de fusão, composições, ácido nucleico,vetor, célula hospedeira, métodos de produção de uma proteína de fusão, de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana, de tratamento da lesão renal, para acelerar ou melhorar a cicatrização, para a prevenção ou tratamento de uma condição cardiovascular, para tratamento da síndrome metabólica e para tratamento da endotoxemia. | |
CA2848762C (en) | Method for treatment of disorders of the gastrointestinal system | |
CO6680687A2 (es) | Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas | |
UA108193C2 (uk) | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
EA201270758A1 (ru) | Мутанты fgf21 и их применение | |
MX359953B (es) | Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada. | |
EA201000424A1 (ru) | Антитела к il-23 | |
BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
BR112013028709A2 (pt) | cepas bacterianas capazes de metabolizar oxalatos | |
BR112012030337A2 (pt) | vacinas compreendendo colesterol e cpg como moléculas veículo-adjuvante exclusivas e uso das mesmas | |
BR112012028893A2 (pt) | composições imunoestimuladoras e de vacina | |
BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/01/2011 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B25D | Requested change of name of applicant approved |
Owner name: INSTITUT PASTEUR (FR) ; UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M.) (FR) ; INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) |
|
B25A | Requested transfer of rights approved |
Owner name: INSTITUT PASTEUR (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M.) (FR) ; INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) ; UNIVERSITE DE PARIS (FR) |
|
B25D | Requested change of name of applicant approved |
Owner name: INSTITUT PASTEUR (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M.) (FR) ; INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) ; UNIVERSITE PARIS CITE (FR) |